Dynavax to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2020 financial results on November 5, 2020, after U.S. markets close. A conference call with live audio webcast is scheduled at 4:30 p.m. ET. The company is known for developing novel vaccines, including HEPLISAV-B®, a hepatitis B vaccine. Further developments include collaborations on adjuvanted vaccines targeting COVID-19 and influenza. For detailed information, visit www.dynavax.com.

EMERYVILLE, Calif., Oct. 22, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report third quarter 2020 financial results on Thursday, November 5, 2020, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 1475431.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2020-financial-results-and-host-conference-call-on-november-5-2020-301158328.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its third quarter 2020 financial results?

Dynavax will report its third quarter 2020 financial results on November 5, 2020, after U.S. markets close.

What is the time for Dynavax's conference call on November 5, 2020?

The conference call is scheduled for 4:30 p.m. ET on November 5, 2020.

Where can I access the Dynavax conference call?

You can access the conference call via the 'Events & Presentations' page on the Investors section of Dynavax's website.

What is Dynavax's first commercial product?

Dynavax's first commercial product is HEPLISAV-B®, a hepatitis B vaccine.

What collaborations is Dynavax involved in?

Dynavax is collaborating on adjuvanted vaccines for COVID-19 and influenza.